Krka Logo

Krka

Develops and sells generic prescription, non-prescription, and animal health products globally.

KRKG | LJSE

Overview

Corporate Details

ISIN(s):
SI0031102120
LEI:
549300H9RLRTRTLRUZ73
Country:
Slovenia
Address:
Šmarješka cesta 006, 8501 Novo mesto
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Krka is a leading international generic pharmaceutical company focused on the development, production, marketing, and sale of human and animal health products. With over 70 years of experience, the company's core business is providing high-quality and innovative generic medicines. Its portfolio is composed of three main segments: prescription pharmaceuticals for treating common diseases, non-prescription products for minor illnesses and preventative care, and a range of animal health products. Krka's products are marketed globally, serving patients in more than 70 countries.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-01 08:30
Transaction in Own Shares
Terminski načrt programa odkupa lastnih delnic v prvem polletju 2026
English 110.6 KB
2025-12-01 08:30
Transaction in Own Shares
Terminski načrt programa odkupa lastnih delnic v prvem polletju 2026
Slovene 1.5 KB
2025-12-01 08:30
Transaction in Own Shares
Share buy-back programme schedule from January to June 2026
English 111.8 KB
2025-12-01 08:30
Transaction in Own Shares
Share buy-back programme schedule from January to June 2026
English 1.5 KB
2025-12-01 08:30
Transaction in Own Shares
Detailed report on acquisition of treasury shares
English 122.3 KB
2025-12-01 08:30
Transaction in Own Shares
Acquisition of treasury shares
English 2.3 KB
2025-12-01 08:30
Transaction in Own Shares
Podrobno poročilo o nakupih lastnih delnic
English 118.8 KB
2025-12-01 08:30
Transaction in Own Shares
Pridobivanje lastnih delnic
Slovene 2.1 KB
2025-12-01 08:30
Report Publication Announcement
Financial Calendar 2026
English 69.6 KB
2025-12-01 08:30
Report Publication Announcement
Financial calendar for 2026
English 1.0 KB
2025-12-01 08:30
Report Publication Announcement
Finančni koledar 2026
Slovene 104.0 KB
2025-12-01 08:30
Report Publication Announcement
Finančni koledar za leto 2026
Slovene 1.1 KB
2025-11-24 08:30
Transaction in Own Shares
Detailed report on acquisition of treasury shares
English 122.6 KB
2025-11-24 08:30
Transaction in Own Shares
Acquisition of treasury shares
English 2.2 KB
2025-11-24 08:30
Transaction in Own Shares
Podrobno poročilo o nakupih lastnih delnic
English 119.2 KB

Automate Your Workflow. Get a real-time feed of all Krka filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Krka

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Krka via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM

Talk to a Data Expert

Have a question? We'll get back to you promptly.